The global breast biopsy devices market size was exhibited at USD 1 billion in 2022 and is projected to hit around USD 1.52 billion by 2032 with a registered CAGR of 4.3% during the forecast period 2023 to 2032.
Breast biopsy techniques employ medical instruments known as breast biopsy devices. A breast biopsy is a surgical procedure that removes tissue or fluid to be examined and checked for any illnesses. Under microscopes, the excised tissue is analyzed to see whether it contains cancer.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Once a patient has a cancer diagnosis, a biopsy is a medical examination to analyze and remove the malignant tissue from the body. To obtain tissue samples for the diagnosis of the condition, a biopsy is used. Skin biopsy, shave biopsy, fine needle aspiration, incision, excision biopsy core, and vacuum-assisted biopsy are only a few of the biopsy procedures used in the diagnosis of malignancies. The main factor driving the growth of the global Breast Biopsy Device Market is an increase in the incidence of breast cancer. The market is now growing due to the expansion of breast cancer screening programs as well as the surgical acceptance of minimally invasive breast biopsies.
The market is expanding as a result of technical improvements and advancements in breast biopsy instruments. However, the expensive cost of breast biopsy and its numerous negative side effects might limit market expansion. Vendor promotion possibilities have been made essential by the increased prevalence of breast cancer. Important market players focus on expanding their product ranges and winning approvals for their goods. To spread the word and raise awareness about cancer, there are several platforms, including conferences that may be used.
Additionally, several public and private institutions sponsor and award grants to companies that develop novel goods with cutting-edge technology solutions to detect breast cancer in its early stages. These elements may have a major impact on market expansion throughout the anticipated term.
Report Scope of the Breast Biopsy Devices Market
|Market Size in 2023
|USD 1.04 Billion
|Market Size by 2032
|USD 1.52 Billion
|Growth Rate from 2023 to 2032
|CAGR of 4.3%
|Fastest Growing Market
|2023 to 2032
Key Market Drivers
Year to Year growth in the incidence of breast cancers
Key Market Challenges
Risks associated with the use of breast biopsy devices
Key Market Opportunities
The burgeoning number of breast cancer patients
A rise in government initiatives coupled with an increase in cancer awareness screening programs
Product Type Insights
Due to the rising popularity of image-guided procedures in both developed and developing countries as well as the development of cutting-edge and distinctive designs, the biopsy needles market is predicted to account for a sizeable portion of the breast biopsy market. Consider the tri-axial needle, which has a cutting needle on the exterior, a pincer needle on the outside, and a sharp style within. Healthcare professionals may cut through tissue without crushing it because of the needle's shape. Despite its unusual shape, the needle is clearly visible with CT and ultrasonography, which are frequently utilized for biopsy guidance.
The Guidance category with respect to liquid biopsy is anticipated to grow the most over the forecast period. A revolutionary technique that is broadening the range of cancer diagnostics is a liquid biopsy. The significant growth of the market may be attributed to the expanding use of cutting-edge NGS-based assays and droplet digital PCR technology for conducting liquid biopsies in the majority of developed nations. To bring new products to market, businesses in the sector are increasing their R&D spending. Thus, ongoing clinical trials and a prospective product pipeline will fuel additional market expansion.
This sector is divided into needle breast and open surgical biopsies according to kind. The first is further divided into vacuum-assisted core biopsy, core-needle aspiration, and both. Due mostly to an increase in demand for less invasive treatments, the fine-needle aspiration category is predicted to have the highest share in 2022. Contrarily, the less invasive vacuum-assisted core biopsy, which entails creating a tiny incision through which the needle is put, followed by sample collection using a vacuum-powered device, is predicted to expand at a high CAGR value throughout the projection period.
North America accounted for the largest revenue share in the worldwide market in 2022, and it is anticipated that the region would continue to dominate the market during the forecast period. The U.S. and Canada, two of the region's biggest economies, are the main sources of income for the market value in the area. The prospective market for medical tourism in the area underpins the value of the prevailing regional market.
Furthermore, Asia Pacific is anticipated to grow at the fastest rate from 2022 to 2030, according to projections. The rapidly developing nations in the area have invested in the building of healthcare infrastructure, which is promoting the market growth. China, the world's second-largest economy, is expected to expand at a CAGR of 13.1% between 2022 and 2030, with a target market size of US$620.6 million. Other major geographic markets include Japan and Canada, which are expected to increase at rates of 4.8% and 7.8%, respectively, between 2022 and 2030. Germany is expected to expand within Europe at a rate of growth of around 5.8% CAGR. Additionally, as the diagnostic market in developing nations becomes more aware of breast biopsy procedures, businesses are able to invest in breast biopsy equipment in these developing markets. Rapid advancements in health technology in nations like China, India, and South Korea have prompted hospitals and other breast care facilities to make large expenditures in cutting-edge technologies (comprising liquid breast biopsy and vacuum-assisted biopsy devices, amongst others). For instance, Cytecare Hospital in Bengaluru, India, was acknowledged as the first hospital to offer 3D mammography (Digital Breast Tomosynthesis) to female patients. Since 3D Mammography creates many successive slides through the tissues using low concentrations of x-rays at various angles, it offers an advantage over 2D scans. The scans take 10 seconds, after which the computer receives the conclusions.
In March 2019, Dune Medical Devices revealed the results of the first human test of their smart biopsy device. The smart Biopdy from Dune Medical is a continuous soft tissue biopsy device that provides electrical samples in real time using small key needle detectors. To enhance diagnosis and readout, these electrical pulses are compared to astronomical data. The in-man stage signals the start of a more involved, exhaustive clinical investigation aimed at identifying the precise tissue makeup of the breast.
Key Market Players
Segment Covered in the Report
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client